Andrew J. Aguirre
Uses organoids and functional genomics to find what pancreatic cancers depend on beyond KRAS.
Physician-scientist who led real-time genomic profiling of pancreatic cancer and studies RAS-pathway dependencies and resistance to RAS inhibitors.
| Title | Journal | Year |
|---|---|---|
| Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine | Cancer Discovery | 2018 |
Pages like this
not linked directly; found by shared links- ProductMRTX1133
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- ProductOlomorasib
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- PersonDavid A. Tuveson
Shares Lustgarten Foundation, Patient-derived organoids, Pancreatic ductal adenocarcinoma.
- ProductElironrasib
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- TrialRASolute 302
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- PersonFrank McCormick
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- CompanyVerastem Oncology
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.